Autoantibody response to a novel tumor-associated antigen p90/CIP2A in breast cancer immunodiagnosis

Tumor Biology

Volumn 35, Issue 3, 2014, Pages 2661-2667

  Liu, Xinxin ^a,b   Chai, Yurong ^b   Li, Jitian ^b   Ren, Pengfei ^a,b   Liu, Mei ^b   Dai, Liping ^a,b   Qian, Wei ^b   Li, Wenjie ^a   Zhang, Jian Ying ^a,b  

^a ZHENGZHOU UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS AT EL PASO   (United States)

Author keywords

Breast cancer; Immunodiagnosis; p90 CIP2A; Tumor associated antigen

Indexed keywords

AUTOANTIBODY; PROTEIN P90; TUMOR ANTIGEN; TUMOR MARKER;

ANTIBODY RESPONSE; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER SCREENING; CANCER STAGING; CANCER TISSUE; CONTROLLED STUDY; EARLY CANCER; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; WESTERN BLOTTING;

ANTIGENS, NEOPLASM; AUTOANTIBODIES; AUTOANTIGENS; BLOTTING, WESTERN; BREAST NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE PROTEINS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84899066271     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1350-6     Document Type: Article

References (45)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46:765-81.
3. Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet. 2011;377:127-38.
4. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
5. Tan EM. Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J Clin Invest. 2001;108:1411-5.
6. Tan EM, Zhang J. Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol Rev. 2008;222:328-40.
7. Soussi T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 2000;60:1777-88.
8. Looi K, Megliorino R, Shi FD, Peng XX, Chen Y, Zhang JY. Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies. Oncol Rep. 2006;16:1105-10.
9. Zhang JY, Chan EK, Peng XX, Tan EM. A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma. J Exp Med. 1999;189:1101-10.
10. Soo Hoo L, Zhang JY, Chan EK. Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer. Oncogene. 2002;21:5006-15.
11. Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Bottzauw T, et al. CIP2A inhibits PP2A in human malignancies. Cell. 2007;130:51-62.
12. Chen KF, Yeh PY, Hsu C, Hsu CH, Lu YS, Hsieh HP, et al. Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem. 2009;284:11121-33.
13. Chen KF, Liu CY, Lin YC, Yu HC, Liu TH, Hou DR, et al. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene. 2010;29:6257-66.
14. Dong QZ, Wang Y, Dong XJ, Li ZX, Tang ZP, Cui QZ, et al. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol. 2011;18:857-65.
15. Katz J, Jakymiw A, Ducksworth MK, Stewart CM, Bhattacharyya I, Cha S, et al. CIP2A expression and localization in oral carcinoma and dysplasia. Cancer Biol Ther. 2010;10:694-9.
16. Khanna A, Bockelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, et al. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst. 2009;101:793-805.
17. Vaarala MH, Vaisanen MR, Ristimaki A. CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res. 2010;29:136.
18. Wang J, Li W, Li L, Yu X, Jia J, Chen C. CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation. Int J Lab Hematol. 2011;33:290-8.
19. Chen Y, Zhou Y, Qiu S, Wang K, Liu S, Peng XX, et al. Autoantibodies to tumor-associated antigens combined with abnormal alpha-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma. Cancer Lett. 2010;289:32-9.
20. Li W, Ge Z, Liu C, Liu Z, Bjorkholm M, Jia J, et al. CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. Clin Cancer Res. 2008;14:3722-8.
21. Teng HW, Yang SH, Lin JK, Chen WS, Lin TC, Jiang JK, et al. CIP2A is a predictor of poor prognosis in colon cancer. J Gastrointest Surg. 2012;16:1037-47.
22. Ren J, Li W, Yan L, Jiao W, Tian S, Li D, et al. Expression of CIP2A in renal cell carcinomas correlates with tumour invasion, metastasis and patients' survival. Br J Cancer. 2011;105:1905-11.
23. Basile JR, Czerninski R. The role of CIP2A in oral squamous cell carcinoma. Cancer Biol Ther. 2010;10:700-2.
24. Bockelman C, Koskensalo S, Hagstrom J, Lundin M, Ristimaki A, Haglund C. CIP2A overexpression is associated with c-Myc expression in colorectal cancer. Cancer Biol Ther. 2012;13:289-95.
25. Tseng LM, Liu CY, Chang KC, Chu PY, Shiau CW, Chen KF. CIP2A is a target of bortezomib in human triple negative breast cancer cells. Breast Cancer Res BCR. 2012;14:R68.
26. Come C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, et al. CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res. 2009;15:5092-100.
27. Desmetz C, Cortijo C, Mange A, Solassol J. Humoral response to cancer as a tool for biomarker discovery. J Proteomics. 2009;72:982-8.
28. Liu W, Peng B, Lu Y, Xu W, Qian W, Zhang JY. Autoantibodies to tumor-associated antigens as biomarkers in cancer immunodiagnosis. Autoimmun Rev. 2011;10:331-5.
29. Chapman C, Murray A, Chakrabarti J, Thorpe A, Woolston C, Sahin U, et al. Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol. 2007;18:868-73.
30. Desmetz C, Bibeau F, Boissiere F, Bellet V, Rouanet P, Maudelonde T, et al. Proteomics-based identification of HSP60 as a tumor-associated antigen in early stage breast cancer and ductal carcinoma in situ. J Proteome Res. 2008;7:3830-7.
31. Pereira-Faca SR, Kuick R, Puravs E, Zhang Q, Krasnoselsky AL, Phanstiel D, et al. Identification of 14-3-3 theta as an antigen that induces a humoral response in lung cancer. Cancer Res. 2007;67:12000-6.
32. Park BW, Oh JW, Kim JH, Park SH, Kim KS, Lee KS. Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol. 2008;19:675-81.
33. Hu S, Loo JA, Wong DT. Human body fluid proteome analysis. Proteomics. 2006;6:6326-53.
34. Downes MR, Byrne JC, Dunn MJ, Fitzpatrick JM, Watson RW, Pennington SR. Application of proteomic strategies to the identification of urinary biomarkers for prostate cancer: a review. Biomark Biochem Indic Expo Response Susceptibility Chem. 2006;11:406-16.
35. Chang JW, Kang UB, Kim DH, Yi JK, Lee JW, Noh DY, et al. Identification of circulating endorepellin LG3 fragment: potential use as a serological biomarker for breast cancer. Proteomics Clin Appl. 2008;2:23-32.
36. Caron M, Choquet-Kastylevsky G, Joubert-Caron R. Cancer immunomics using autoantibody signatures for biomarker discovery. Mol Cell Proteomics MCP. 2007;6:1115-22.
37. Madrid FF, Maroun MC. Serologic laboratory findings in malignancy. Rheum Dis Clin North Am. 2011;37:507-25.
38. Hong SH, Misek DE, Wang H, Puravs E, Giordano TJ, Greenson JK, et al. An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer. Cancer Res. 2004;64:5504-10.
39. Himoto T, Kuriyama S, Zhang JY, Chan EK, Nishioka M, Tan EM. Significance of autoantibodies against insulin-like growth factor II mRNA-binding proteins in patients with hepatocellular carcinoma. Int J Oncol. 2005;26:311-7.
40. Ersvaer E, Zhang JY, McCormack E, Olsnes A, Anensen N, Tan EM, et al. Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients. Eur J Haematol. 2007;79:210-25.
41. Zhang J, Wang K, Liu SS, Dai L, Zhang JY. Using proteomic approach to identify tumor-associated proteins as biomarkers in human esophageal squamous cell carcinoma. J Proteome Res. 2011;10:2863-72.
42. Disis ML, Cheever MA. HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv Cancer Res. 1997;71:343-71.
43. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287-312.
44. Duffy MJ. Serum tumor markers in breast cancer: are they of clinical value? Clin Chem. 2006;52:345-51.
45. Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, et al. Tumor markers in breast cancer - European Group on Tumor Markers recommendations. Tumour Biol. 2005;26:281-93.